Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 17/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 17/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244238 | 0.86 | GFER (0.63) | ALDH1A1CYP3A4MTNR1AMTNR1BGFER | |
| SCHEMBL29387324 | 0.86 | GFER (0.63) | ALDH1A1CYP3A4MTNR1AMTNR1BGFER | |
| SCHEMBL14369182 | 0.84 | ALDH1A1 (0.55) | ALDH1A1CYP3A4MTNR1AMTNR1BGFER | |
| SCHEMBL11323791 | 0.83 | MTNR1A (0.52) | ALDH1A1MTNR1AMTNR1BGFERMEN1 | |
| SCHEMBL6665261 | 0.83 | MTNR1A (0.52) | MTNR1AMTNR1BGFERMEN1GAA | |
| SCHEMBL8978503 | 0.83 | MTNR1A (0.68) | ALDH1A1MTNR1AMTNR1BGFERMEN1 | |
| SCHEMBL27964845 | 0.82 | MTNR1B (0.54) | MTNR1AMTNR1BGFERMEN1GAA | |
| SCHEMBL17066857 | 0.80 | MTNR1B (0.77) | MTNR1AMTNR1B | |
| SCHEMBL10782495 | 0.78 | ALDH1A1 (0.79) | ALDH1A1CYP3A4 | |
| SCHEMBL10620447 | 0.78 | GFER (0.55) | ALDH1A1CYP3A4GFERMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449315-B2 | Bifunctional energy-reversible acyl-compositions | CRYOLIFE, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070167644-A1 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | CRYOLIFE, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| EP-1392204-A4 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | CRYOLIFE INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7157458-B2 | Bifunctional energy-reversible acyl-compositions | CRYOLIFE, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060106204-A1 | Bifunctional energy-reversible acyl-compositions | GILBERT CARL W | 2006-05-18 | — | — | US | disclosed |
| EP-1392204-A2 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | CryoLife, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20020187993-A1 | Bifunctional energy-reversible acyl-compositions | CRYOLIFE, INC. | 2002-12-12 | — | — | US | disclosed |
| WO-2002083030-A2 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | CRYOLIFE, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187993-A1 | Bifunctional energy-reversible acyl-compositions | ACACB, ACACA, ACAT1 | ALDH1A1 951/4885CYP3A4 2478/4885MTNR1A 1586/4885 |
| US-20070167644-A1 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | ACACB, ACAT1, ACACA | ALDH1A1 1248/4885CYP3A4 2527/4885MTNR1A 1637/4885 |
| US-20060106204-A1 | Bifunctional energy-reversible acyl-compositions | ACACB, ACAT1, ACACA | ALDH1A1 1248/4885CYP3A4 2527/4885MTNR1A 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.